An NCI oral history with Paul Marks

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In 1999, NCI recorded an oral history with Paul Marks, president and chief executive officer of Memorial Sloan Kettering Cancer Center from 1980-1999. Marks died April 28, 2021, at the age of 93. An obituary appears here in The Cancer Letter

In the NCI interview, Marks describes his initial skepticism of the National Cancer Act. 

“I, frankly, was very concerned that it would distort the funding for biomedical research. I felt that a most important area for funding was basic research,” he said. “By definition, this couldn’t be defined as cancer research or heart research or diabetes, but fundamental investigations into human biology, or mammalian biology, or even lower forms [of life] was extremely important and had to go forward if we were really to understand and make progress in the cancer problem.” 

Marks sent a letter outlining his concerns to Benno Schmidt, one of the architects of the National Cancer Program, who set up a meeting with Marks and the head of NCI at the time. 

Marks went on to join the President’s Cancer Panel from 1976 through 1979. In this interview, he describes this journey among other career highlights. 

Editor’s Note: This article, which was first posted on the website of Memorial Sloan Kettering Cancer Center in 2017, discusses the influence of former MSK President Paul Marks in shaping modern cancer research. 

The cells weren’t supposed to turn pink, Charlotte Friend thought to herself as she stared into a glass tube on her lab bench at Mount Sinai hospital in 1971.

Dr. Friend, a microbiologist, had been experimenting with a virus that caused cancer in mice. The virus infected mouse cells then hijacked the cells’ genetic machinery, leading to leukemia.

In this particular experiment, she first soaked the cells in a chemical called DMSO. She hoped to make the cells more porous, enabling more virus particles to enter. A few days later, the normally clear solution of leukemia cells had turned bright pink.

Dr. Friend phoned the one person she thought might have some insight.

“What human proteins are red?” she asked Paul Marks, a professor of clinical pathology at Columbia University whom she knew to be an expert in the genetics of blood disorders.

“There’s only one,” Dr. Marks replied.

Paul Marks was president and CEO of Memorial Sloan Kettering Cancer Center from 1980-1999. To commemorate the 50th anniversary of the National Cancer Act, MSK developed an interactive timeline that outlines its most significant contributions to oncology during the past half century. 


Quote of the week

Most of the answers to cancer lie down on the level of the genes, in our understanding of how cells differentiate and divide.

Paul Marks

Recent article

Inspired by the 50th anniversary of the National Cancer Act, AACI is pleased to share The History of the Association of American Cancer Institutes. Written by Donald L. Trump, MD, and Eric T. Rosenthal, authors of Centers of the Cancer Universe: A Half-Century of Progress Against Cancer (Rowman & Littlefield, 2021), the AACI history is based on meeting minutes, other source documents and interviews with AACI past presidents.


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available. 

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login